METTLER-TOLEDO INTERNATIONAL (MTD) Stock Fundamental Analysis
NYSE:MTD - US5926881054 - Common Stock
1268.6 USD
-7.4 (-0.58%)
1268.6 USD
0 (0%)
MTD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. MTD scores excellent on profitability, but there are some minor concerns on its financial health. MTD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MTD was profitable.
In the past year MTD had a positive cash flow from operations.
In the past 5 years MTD has always been profitable.
MTD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of MTD (24.40%) is better than 98.18% of its industry peers.
MTD's Return On Invested Capital of 39.61% is amongst the best of the industry. MTD outperforms 96.36% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MTD is significantly above the industry average of 15.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.4% | ||
| ROE | N/A | ||
| ROIC | 39.61% |
ROA(3y)25.04%
ROA(5y)23.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)41.86%
ROIC(5y)39.3%
1.3 Margins
With an excellent Profit Margin value of 21.46%, MTD belongs to the best of the industry, outperforming 94.55% of the companies in the same industry.
In the last couple of years the Profit Margin of MTD has grown nicely.
With an excellent Operating Margin value of 28.61%, MTD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of MTD has grown nicely.
MTD has a Gross Margin of 59.94%. This is in the better half of the industry: MTD outperforms 78.18% of its industry peers.
In the last couple of years the Gross Margin of MTD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.61% | ||
| PM (TTM) | 21.46% | ||
| GM | 59.94% |
OM growth 3Y2.77%
OM growth 5Y3.56%
PM growth 3Y2.52%
PM growth 5Y3.63%
GM growth 3Y0.93%
GM growth 5Y0.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MTD is creating value.
The number of shares outstanding for MTD has been reduced compared to 1 year ago.
The number of shares outstanding for MTD has been reduced compared to 5 years ago.
The debt/assets ratio for MTD is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 10.17 indicates that MTD is not in any danger for bankruptcy at the moment.
MTD's Altman-Z score of 10.17 is amongst the best of the industry. MTD outperforms 94.55% of its industry peers.
MTD has a debt to FCF ratio of 2.58. This is a good value and a sign of high solvency as MTD would need 2.58 years to pay back of all of its debts.
The Debt to FCF ratio of MTD (2.58) is better than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.58 | ||
| Altman-Z | 10.17 |
ROIC/WACC3.84
WACC10.31%
2.3 Liquidity
MTD has a Current Ratio of 1.12. This is a normal value and indicates that MTD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.12, MTD is doing worse than 85.45% of the companies in the same industry.
MTD has a Quick Ratio of 1.12. This is a bad value and indicates that MTD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.77, MTD is not doing good in the industry: 89.09% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.37% over the past year.
MTD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.53% yearly.
The Revenue has been growing slightly by 3.10% in the past year.
The Revenue has been growing slightly by 5.18% on average over the past years.
EPS 1Y (TTM)8.37%
EPS 3Y6.67%
EPS 5Y12.53%
EPS Q2Q%4.56%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y1.37%
Revenue growth 5Y5.18%
Sales Q2Q%3.85%
3.2 Future
Based on estimates for the next years, MTD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.06% on average per year.
MTD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.03% yearly.
EPS Next Y2.96%
EPS Next 2Y6.58%
EPS Next 3Y8.13%
EPS Next 5Y9.06%
Revenue Next Year3.3%
Revenue Next 2Y3.85%
Revenue Next 3Y4.32%
Revenue Next 5Y4.03%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 31.02, which means the current valuation is very expensive for MTD.
65.45% of the companies in the same industry are more expensive than MTD, based on the Price/Earnings ratio.
MTD is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.84, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 27.13 indicates a quite expensive valuation of MTD.
MTD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MTD is cheaper than 69.09% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.48. MTD is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.02 | ||
| Fwd PE | 27.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MTD is valued a bit cheaper than the industry average as 67.27% of the companies are valued more expensively.
67.27% of the companies in the same industry are more expensive than MTD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.82 | ||
| EV/EBITDA | 23.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MTD does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MTD may justify a higher PE ratio.
PEG (NY)10.49
PEG (5Y)2.48
EPS Next 2Y6.58%
EPS Next 3Y8.13%
5. Dividend
5.1 Amount
No dividends for MTD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1268.6
-7.4 (-0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.05%
Inst Owner Change-1%
Ins Owners0.42%
Ins Owner Change2.98%
Market Cap26.13B
Analysts71.58
Price Target1311.82 (3.41%)
Short Float %3.44%
Short Ratio4.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.38%
Min EPS beat(2)2.78%
Max EPS beat(2)3.98%
EPS beat(4)4
Avg EPS beat(4)3.18%
Min EPS beat(4)1.02%
Max EPS beat(4)4.94%
EPS beat(8)6
Avg EPS beat(8)3.16%
EPS beat(12)10
Avg EPS beat(12)2.65%
EPS beat(16)14
Avg EPS beat(16)3.36%
Revenue beat(2)1
Avg Revenue beat(2)0.73%
Min Revenue beat(2)-0.18%
Max Revenue beat(2)1.63%
Revenue beat(4)3
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-0.18%
Max Revenue beat(4)2.56%
Revenue beat(8)5
Avg Revenue beat(8)0.5%
Revenue beat(12)8
Avg Revenue beat(12)0.25%
Revenue beat(16)12
Avg Revenue beat(16)0.61%
PT rev (1m)0.83%
PT rev (3m)0.8%
EPS NQ rev (1m)1.24%
EPS NQ rev (3m)-4.16%
EPS NY rev (1m)0.93%
EPS NY rev (3m)1.1%
Revenue NQ rev (1m)1.16%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)1.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.02 | ||
| Fwd PE | 27.13 | ||
| P/S | 6.76 | ||
| P/FCF | 30.82 | ||
| P/OCF | 27.46 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.13 |
EPS(TTM)40.9
EY3.22%
EPS(NY)46.75
Fwd EY3.69%
FCF(TTM)41.16
FCFY3.24%
OCF(TTM)46.2
OCFY3.64%
SpS187.7
BVpS-12.56
TBVpS-58.08
PEG (NY)10.49
PEG (5Y)2.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.4% | ||
| ROE | N/A | ||
| ROCE | 48.24% | ||
| ROIC | 39.61% | ||
| ROICexc | 40.71% | ||
| ROICexgc | 70.2% | ||
| OM | 28.61% | ||
| PM (TTM) | 21.46% | ||
| GM | 59.94% | ||
| FCFM | 21.93% |
ROA(3y)25.04%
ROA(5y)23.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)41.86%
ROIC(5y)39.3%
ROICexc(3y)43.32%
ROICexc(5y)40.86%
ROICexgc(3y)78.59%
ROICexgc(5y)73.33%
ROCE(3y)50.98%
ROCE(5y)47.86%
ROICexcg growth 3Y5.41%
ROICexcg growth 5Y8.89%
ROICexc growth 3Y5.36%
ROICexc growth 5Y6.84%
OM growth 3Y2.77%
OM growth 5Y3.56%
PM growth 3Y2.52%
PM growth 5Y3.63%
GM growth 3Y0.93%
GM growth 5Y0.74%
F-Score7
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.58 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 85.07% | ||
| Cap/Sales | 2.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 77.47% | ||
| Profit Quality | 102.18% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 10.17 |
F-Score7
WACC10.31%
ROIC/WACC3.84
Cap/Depr(3y)92.83%
Cap/Depr(5y)94.35%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.89%
Profit Quality(3y)97.94%
Profit Quality(5y)100.58%
High Growth Momentum
Growth
EPS 1Y (TTM)8.37%
EPS 3Y6.67%
EPS 5Y12.53%
EPS Q2Q%4.56%
EPS Next Y2.96%
EPS Next 2Y6.58%
EPS Next 3Y8.13%
EPS Next 5Y9.06%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y1.37%
Revenue growth 5Y5.18%
Sales Q2Q%3.85%
Revenue Next Year3.3%
Revenue Next 2Y3.85%
Revenue Next 3Y4.32%
Revenue Next 5Y4.03%
EBIT growth 1Y4.27%
EBIT growth 3Y4.18%
EBIT growth 5Y8.92%
EBIT Next Year5.85%
EBIT Next 3Y6.25%
EBIT Next 5Y6.82%
FCF growth 1Y-1.24%
FCF growth 3Y2.57%
FCF growth 5Y11.3%
OCF growth 1Y-1.81%
OCF growth 3Y2.14%
OCF growth 5Y9.92%